Background. Patterns of cause-specific mortality in individuals infected with human immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (ART).
Antiretroviral therapy (ART) has dramatically reduced mortality for people living with human immunodeficiency virus (HIV), or PLWH, allowing life expectancy for those successfully treated to approach that of the general population [1] [2] [3] . However, overall mortality among PLWH remains higher than in the general population [4] [5] [6] . As the HIV-infected population ages and duration on ART increases, the distribution of causes of death and associations with patient characteristics are changing. The proportion of AIDS-related deaths in PLWH has decreased in the ART era [7, 8] , and decreases with duration on ART [9] . In high-income countries, there is concern over excess mortality from cancer [6, [10] [11] [12] and cardiovascular disease (CVD) [6] . Appropriate management of HIV disease and associated comorbidities may result in further decreases in mortality, but will depend on a detailed understanding of causes of death.
Based on a large collaboration of cohorts of PLWH in whom causes of death were classified according to standardized procedures, we assessed how patterns of causes of death change with time since starting ART. We estimated associations of patient characteristics with specific causes of death in the first year after starting ART and in subsequent years.
METHODS

Cohorts and Patients
The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of cohort studies of PLWH from Europe and North America [13] (available at: http://www.bris.ac.uk/art-cc). Prospective cohorts were eligible if they had enrolled at least 100 HIV type 1 (HIV-1)-infected patients aged ≥16 years who were not previously exposed to antiretroviral drugs and started ART with at least 3 drugs, including nucleoside reverse transcriptase inhibitors, protease inhibitors, or nonnucleoside reverse transcriptase inhibitors, with a median follow-up of ≥1 year. All cohorts use quality control procedures. The database was updated in September 2010. Institutional review boards approved data collection at all sites according to local requirements. The National Health Service Health Research Authority South West-Cornwall and Plymouth Research Ethics Committee, United Kingdom, has approved the ART-CC study (REC reference 12/SW/0253).
Coding Causes of Death
Information on cause of death was recorded by 16 cohorts (Appendix) either as International Classification of Diseases, Ninth Revision (ICD-9) or Tenth Revision (ICD-10), Classification based on the Coding of Death in HIV (CoDe) project (available at: http://www.chip.dk/CoDe/tabid/55/Default.aspx), or free text. We adapted the CoDe protocol [14] to classify causes of death into mutually exclusive categories. Clinicians classified deaths using summary tables of patient details that included ICD-9/ICD-10 codes or free text for cause of death, patient characteristics at ART initiation (age, sex, transmission risk group, AIDS-defining conditions, and hepatitis C status), time from ART initiation to death, AIDS-defining conditions after starting ART, latest CD4 (within 6 months of death), and whether a patient was on ART at time of death. A computer algorithm developed by the Mortalité 2000-2005 Study Group [15] classified deaths using ICD-10 codes, when available. When ICD-10 codes were not available, 2 clinicians independently classified each death. Disagreements between clinicians and/or computerassigned codes were resolved via panel discussion as per the CoDe protocol described previously [9] . Further information on rules to classify deaths is provided in the Supplementary Data.
We grouped causes of death with a frequency of <20 as "other." AIDS was defined according to the 1993 Centers for Disease Control and Prevention classification [16] and included CoDe 01 (unspecified AIDS), 01.1 (AIDS infection), and 01.2 (AIDS malignancy). We grouped deaths as AIDS, non-AIDS infection, liver-related (hepatitis and liver failure, CoDe 03 and 14), non-AIDS nonhepatitis malignancy (CoDe 04), cardiovascular disease (myocardial infarction/ischemic heart disease, CoDe 08, and stroke, CoDe 09), heart/vascular disease (heart failure/unspecified, and other heart disease, CoDe 24), respiratory disease (chronic obstructive lung disease, CoDe 13 and 25), renal failure (CoDe 15), disease of the central nervous system (CoDe 23), unnatural deaths (accident/violent, suicide, and overdose, CoDe 16, 17, and 19) , and other (CoDe 90).
Statistical Analysis
Follow-up time was calculated from date of starting ART ("baseline") to the earliest of death, last clinic follow-up plus 3 months (because cohorts scheduled visits every 6 months and therefore using the last clinic follow-up date would underestimate follow-up time), or cohort-specific administrative censoring date ("database close"). Crude mortality rates for each cause of death were compared for all patients and by time since starting ART (<0.5, 0.5-0.99, 1-1.99, 2-4.99, and 5-10 years). Crude hazard ratios (HRs) were derived according to age, baseline CD4 count, and risk group. Median CD4 count at death (interquartile range [IQR]) was calculated for each cause of death. To investigate changes in patterns of cause of death over time, and to avoid violation of the proportional hazards assumption, separate Cox models were used to estimate HRs in the first year of ART and in subsequent years. Models were adjusted for sex, risk group (men who have sex with men [MSM], injection drug users [IDUs] , heterosexuals, and other [includes transmission through blood or other unknown routes]), current age ( per decade), baseline CD4 count (<50, 50-99, 100-199, 200-349, ≥350 cells/µL), baseline viral load (<100 000 copies, ≥100 000 copies), AIDS prior to ART, and year of ART initiation (1996-1999, 2000-2003, 2004-2009 ), stratified by cohort. HRs after the first year were adjusted for 12-month CD4 count and viral load (closest measure to 12 months after ART start, within ±3 months) and for AIDS status at 12 months. Patients were classified as having AIDS at 12 months if they had an AIDS diagnosis any time up to 12 months after ART start. Analyses were repeated accounting for competing risks using the method of Fine and Gray [17] . 10 .39 across cohorts. Compared with patients remaining in care, those lost to follow-up were younger, more likely to be IDUs, initiated in earlier years, and had higher baseline CD4 and lower viral load. Table 1 shows patient characteristics at baseline, overall and according to whether death was AIDS or non-AIDS related. The majority of patients were male and infected through sexual contact. Median age was 37 years (IQR, 31-44 years), the median CD4 count was 217 cells/µL (IQR, 96-340), and the median viral load was 70 000 copies/mL (IQR, 14 000-213 684). A total of 14 202 patients (21.8%) had an AIDS diagnosis before ART. Compared with patients who died of AIDS, those who died from non-AIDS causes were older, were more likely to be IDUs, had higher baseline CD4 count and lower viral load, and were less likely to have AIDS prior to ART. Table 2 shows rates of causes of death for all patients, and numbers of deaths and crude HRs according to baseline CD4 (<200 vs ≥200 cells/µL), age (<60 vs ≥60 years), and transmission risk group. The rate of AIDS death was 4.6 (95% CI, 4.3-4.8) per 1000 person-years. Patients with baseline CD4 count ≥200 cells/µL experienced lower rates of each cause of death than those with baseline CD4 count <200 cells/µL, except for unnatural causes and suicide. Rates of cause-specific mortality were higher among older than younger patients, except for unnatural and liver-related deaths. The higher rate of liver-related deaths in younger patients may be explained by the higher proportion of IDUs in this group. Older people had higher rates of malignancy and CVD. Rates for MSM and heterosexuals were broadly similar, although MSM had a higher rate of AIDS malignancy. Patients with presumed transmission via injection drug use had higher rates of all causes of death than other risk groups, particularly deaths from infection, liver disease, and substance abuse. Figure 1 shows rates of selected causes of death by time since starting ART. All-cause mortality rates decreased from 24.3 (95% CI, 22.7-26.1) per 1000 person-years in the first 6 months of ART to 10.2 (95% CI, 9.6-10.9) after 5 years. This was largely due to substantial decreases in AIDS-related death, from 13.2 (95% CI, 12.0-14.5) per 1000 person-years in the first 6 months 
RESULTS
Of
Associations of Risk Factors With Mortality According to Time
Since Starting ART Table 4 shows associations of risk factors with cause-specific mortality after the first year of ART. Of 56 756 patients alive and in follow-up 1 year after starting ART, we excluded 9025 (15.9%) patients without 12-month measures of CD4 and viral load (n = 47 731). Of 2326 deaths after the first year, 373 could not be classified and 223 were from other causes. CD4 at 12 months was strongly inversely associated with subsequent rates of AIDS mortality, and also inversely associated with non-AIDS malignancy, non-AIDS infection, and liver-related death. Baseline CD4 was also strongly inversely associated with AIDS, non-AIDS infection, and liver-related mortality after the first year of ART, although the association with non-AIDS malignancy was attenuated compared with the first year. Lack of viral suppression at 12 months was associated with rates of AIDS (HR, 3. , and infection-related (HR, 2.2 [95% CI, 1.3-3.5]) death. Sex differences in cause-specific mortality rates were less pronounced after than during the first year of ART. Age was most strongly associated with death from CVD and non-AIDS malignancy. The effect of age on AIDS deaths declined over time, suggesting that older people are more vulnerable to AIDS in the first year of ART. There was little evidence that rates of cause-specific mortality changed over calendar time, having adjusted for other risk factors. CVD, heart/vascular, and substance abuse deaths were not strongly related to conventional HIV risk factors. Sensitivity analyses accounting for competing risks showed similar associations between risk factors and specific causes of mortality both during and after the first year of ART (data not shown). (6) 85 (7) 62 (5) 27 (2) 31 (3) 21 (2) 41 (3) 10 (1 (28) 326 (14) 178 (8) 184 (8) 106 (5) 78 (3) 64 (3) 111 (5) 40 (2) Transmission risk group 
DISCUSSION
Based on data from a large, multinational cohort collaboration in which causes of death were classified using standardized procedures, both the distribution of causes of death and their associations with patient characteristics differed substantially with time since starting ART. Whereas rates of AIDS death decreased substantially with time since starting ART, rates of non-AIDS malignancy death increased. Higher mortality in men than women during the first year of ART was mostly driven by higher rates of non-AIDS malignancy and liver-related death: between-sex differences decreased with increasing time on ART. Associations with age were strongest for death from CVD, heart/vascular causes, and malignancy. In these data, 46% of patients started ART with a CD4 count <200 cells/µL. There was a persistent role of CD4 count at baseline and 12 months after starting ART in predicting rates of death from AIDS, non-AIDS infection, and non-AIDS malignancy. Lack of viral suppression on ART was strongly associated with death from AIDS and non-AIDS infection, and was also associated with a number of other causes of death. Patients with presumed transmission via injection drug use had persistently high rates of liver-related death, and persistently higher rates of both AIDS and other non-AIDS causes of death. There were several strengths and limitations to this study. Patients were from diverse populations in clinical care across Europe and North America [18] . We compiled a dataset with follow-up on >65 000 patients who experienced >4000 deaths. Thanks to a team of experienced HIV clinicians using standardized procedures, 3574 (84%) deaths were classified as due to specific causes [19] . Disagreements were carefully resolved via panel discussion. Coding was done retrospectively and without complete patient histories, so there will be some misclassification. Classification of cause of death based on autopsy remains the gold standard: clinical classifications may not correlate well with classifications from autopsy reports [20, 21] . However rates of autopsy are diminishing over time [8] . Not all deaths could be classified, which will bias estimates of cause-specific mortality rates downward. Application of a stepwise algorithm to code deaths as AIDS or non-AIDS related could allow broad coding of deaths where specific cause is missing [22] . Data on established risk factors for chronic diseases were not available for all patients and therefore we were unable to estimate their contributions to cause-specific mortality. For example, we do not know whether patients smoke tobacco or abuse alcohol. Some patients classified in the "other" transmission group are likely to have had transmission via injection drug use. Data on ART adherence was not available: this information might provide further insights into patterns of cause-specific mortality but is captured to an extent by viral suppression at 12 months.
The EuroSIDA cohort [23] found little evidence for increased rates of all-cause or non-AIDS-related deaths with long-term cumulative combination ART exposure. By contrast, we found evidence that deaths from non-AIDS malignancy increased with time since ART. An Italian study showed that malignancies, infections, and end-stage liver disease were leading causes of death among PLWH [4] . Studies of the HIV-infected population in France and Switzerland have shown the increasing importance of non-AIDS malignancies, liver disease, and CVD over calendar time [8, 15, 24] and this was seen for non-AIDS malignancies in our previous work [9] . Prevalence of tobacco smoking is known to be higher among PLWH and may contribute substantially to rates of death from CVD and some cancers [25, 26] . Other established chronic disease risk factors may also be more prevalent in HIV-infected populations.
As patients become increasingly treatment experienced, monitoring patterns of causes of death over longer durations of ART will be important for optimizing management of PLWH, many of whom develop comorbidities [27] . Understanding changes in cause-specific deaths with ART duration can help direct appropriate screening procedures, risk assessment, and preventive treatment for PLWH. The well-known high early mortality from AIDS [28, 29] is best addressed by more timely HIV diagnosis and earlier treatment [30] . The persistent role of lower CD4 counts and lack of viral suppression in predicting both AIDS and non-AIDS death after the first year of ART emphasizes the importance of maintaining adherence to therapy and ensuring patients are switched from failing regimens. The association of injection drug use with AIDS deaths was stronger after the first year, which may suggest a role of nonadherence to ART. Mortality later in the course of treatment is increasingly due to non-AIDS malignancies, liver disease, and CVD, whose occurrence also increases with age in HIVuninfected individuals. Continuing study of cause-specific mortality is required to clarify whether such mortality arises from effects of ART, prolonged exposure to the virus, consequences of restoration of CD4 counts after severe immunosuppression, or whether such mortality mainly reflects aging and non-HIV risk factors. Large studies would be required to compare agestandardized mortality rates and risk factors for HIV-infected and -uninfected populations, to quantify excess cause-specific mortality among HIV-infected individuals once known risk factors are accounted for [27] .
To better differentiate mortality risks for those on ART, it will be important to monitor "non-HIV" biomarkers as well as CD4 and viral load. The VACS Index, which includes markers for anemia, liver injury, renal insufficiency, and chronic viral hepatitis as well as factors prognostic for HIV progression, can identify patients at high risk of mortality [31, 32] . Better treatment of hepatitis B and C coinfection [33, 34] , interventions to decrease harm from alcohol or illicit drug abuse, and smoking cessation programs [35] potentially offer opportunities to decrease the risk of diseases that are prevalent among PLWH. US treatment guidelines recommend screening for hepatitis C before starting ART for all PLWH, but annual screening is only recommended for certain subgroups [36] . The European AIDS Clinical Society guidelines recommends screening for certain non-AIDS malignancies in subgroups of PLWH, annual screening for hepatitis C, and management of CVD risk as part of routine clinical care [37] . However, guidelines are not always followed, and improved management of chronic diseases will require close collaboration between specialists.
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